Road to 2025: Global success for this MedTech

Fraser Palamara looks at Compumedics, a company that diagnoses sleeping disorders, monitors neurological afflictions and sophisticated brain analysis.

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.

In this edition, Fraser Palamara looks at Compumedics (ASX:CMP), a company that diagnoses sleeping disorders, monitors neurological afflictions and sophisticated brain analysis. Find out what they plan for 2025 and beyond.

This video was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Road to 2025: Global success for this MedTech